|
市場調査レポート
商品コード
1276796
角膜インプラントの世界市場規模、シェア、産業動向分析レポート:疾患タイプ別、施術タイプ別、エンドユーザー別、地域別展望と予測、2023~2029年Global Corneal Implants Market Size, Share & Industry Trends Analysis Report By Disease Type, By Procedure Type (Penetrating Keratoplasty, Endothelial Keratoplasty, and Others), By End User, By Regional Outlook and Forecast, 2023 - 2029 |
||||||
角膜インプラントの世界市場規模、シェア、産業動向分析レポート:疾患タイプ別、施術タイプ別、エンドユーザー別、地域別展望と予測、2023~2029年 |
出版日: 2023年04月28日
発行: KBV Research
ページ情報: 英文 192 Pages
納期: 即納可能
|
角膜インプラントの市場規模は、2029年までに5億9,510万米ドルに達すると予測され、予測期間中にCAGR6.4%の市場成長率で上昇すると予想されています。
目の角膜は、目の内部組織の保護、屈折力の補助、散乱や光学的劣化を最小限に抑えて網膜に光を集めるなど、いくつかの重要な機能を担っています。角膜移植が必要な疾患には、フックスジストロフィー、円錐角膜、角膜炎、角膜潰瘍、角膜瘢痕、角膜浮腫などがあり、その重症度によっては、角膜移植が必要となります。
角膜のトラブルが多発する中、角膜インプラントの市場は拡大しています。また、新興国市場における角膜失明症の増加や角膜移植の需要も、市場の拡大に寄与しています。角膜インプラント市場の拡大は、ヘルスケア支出とインフラの増加、ヘルスケア分野における政府の政策の転換、可処分所得の増加、製薬産業の発展によって促進されると予想されます。
COVID-19の影響分析
COVID-19のパンデミックは、角膜インプラント市場にダメージを与えました。コストを節約し、感染の危険性を下げるために、多くの病院や診療所が角膜移植などの緊急性のない手術を延期または中止しなければならず、角膜インプラント市場に大きな後退をもたらしました。特に、パンデミックの初期段階では、地元や国の当局による厳しい封鎖規制により、患者の不要不急の治療のための通院が制限されました。角膜形成術や視力回復手術などの眼科手術が、延期可能な選択的手術に分類されたことも、市場の業績をさらに悪化させました。
市場成長要因
角膜失明やその他の視力障害疾患の症例の増加
両側の角膜失明と診断された患者は世界で1,000万人と推定され、角膜疾患は失明の主要原因の1つとなっています。角膜混濁は全体の3.2%で、世界で最も一般的な失明原因の1つに数えられています。世界保健機関(WHO)の新しい報告書によると、トラコーマの患者200万人を含む600万人が、角膜に関連した失明または中程度から重度の視覚障害を持っています。近視または遠視の障害は、全世界で約22億人に影響を及ぼしています。このうち少なくとも10億人、およそ半数は、予防できたはずの視力障害が、対処されなかったケースです。
急増する人工角膜のニーズ
人工角膜は、眼表面疾患、免疫拒絶反応、免疫移植の危険性を克服することができます。人工角膜は膨潤性が低いため、光の散乱や水の蓄積を抑えることができます。角膜失明の有病率の高さと角膜ドナーの不在により、角膜インプラントメーカーには大きな成長率が予想されます。さらに、人工角膜インプラントは、角膜感染症の有病率の増加により、大きな成長が予想されます。このように、従来のものより様々な利点を持つ人工角膜の存在は、角膜インプラント市場の成長を急増させると予想されます。これにより、市場の成長が促進されるでしょう。
市場抑制要因
角膜インプラントの普及を阻む問題点
発展途上国のほとんどのヘルスケア施設では、角膜インプラントを外来手術として扱っています。そのため、これらの地域では角膜インプラントはあまり普及していません。このような地域では、ヘルスケアのインフラが十分でなければ、既存事業や新規事業が市場に参入することは困難です。有望な代替品が利用できるようになったため、角膜内リングセグメント移植術の受容率はここ数年下がり続けています。このように、角膜移植のための手術センターを設立するための高額な資金が必要であること、ドナーの不足などが、市場成長の妨げになると予想されます。
施術タイプの展望
手術タイプに基づき、角膜インプラント市場は、浸透角膜移植術、内皮角膜移植術、その他に区分されます。内皮角膜形成術セグメントは、2022年の角膜インプラント市場においてかなりの収益シェアを獲得しました。これは、最新の角膜移植の種類は、角膜の厚さ全体ではなく、損傷した組織のみを置き換える内皮角膜形成術を使用しているためです。この手術は、感染症や眼球表面の傷の可能性が少ないなどの特徴から、より早く、より良い視力回復を助けるものです。
疾患タイプの展望
角膜インプラント市場は、疾患タイプ別に、円錐角膜、フックスジストロフィー、感染性角膜炎、その他に分類されます。2022年の角膜インプラント市場では、フックスジストロフィー分野が最大の収益シェアを示しました。これは、眼の健康に関する知識の増加や、Fuchs'dystrophyがより一般的であることに起因しています。フックス氏ジストロフィーを患うと、目の前面にある透明な層(角膜)に液体が詰まり、角膜が肥大・肥厚します。その結果、まぶしさ、視界の曇りや障害、目の不快感などが生じることがあります。
エンドユーザーの展望
エンドユーザー別では、角膜インプラント市場は、病院、眼科センター、その他に分類されます。病院セグメントは、2022年の角膜インプラント市場で最も高い収益シェアを記録しました。これは、高度な資格を持つヘルスケア専門家が利用可能であること、民間および団体保険プランの病院ベースのヘルスケアサービスの適用範囲が拡大していることに起因しています。病院には、手術室、集中治療室、特殊な眼科手術用のユニットなど、専門的な機器や設備もあります。したがって、これらの手術を行うための専門家やハイテク機器の存在により、病院分野の成長は予測される期間中に増加すると予想されます。
地域別展望
地域別では、角膜インプラント市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2022年に最大の収益シェアを獲得して角膜インプラント市場をリードしました。この背景には、ヘルスケアのためのインフラが整備され、角膜疾患の有病率が上昇したことがあります。また、人工角膜インプラントの重要な生産者数の急増と、健康と福祉に対する国民の意識の高まりが、この地域の市場成長に寄与しています。さらに、円錐角膜の流行も角膜インプラントの需要を高めると予想され、北米での市場拡大に拍車をかけると期待されています。
List of Figures
The Global Corneal Implants Market size is expected to reach $595.1 Million by 2029, rising at a market growth of 6.4% CAGR during the forecast period.
Sometimes referred to as corneal inlays, corneal implants are optical devices placed into the cornea to improve eyesight. In addition to treating hyperopia, myopia, and astigmatism, the corneal implant technique is performed in cases of keratoconus and other degenerative disorders. Corneal implants are mostly used to treat presbyopia in adults by enhancing close vision and lowering the need for glasses.
A corneal transplant replaces the cornea with a donor or synthetic cornea. In this surgery, artificial or donor corneas are used to replace the cornea. The donor corneas used for transplantation are stored at eye banks in a storage medium. A synthetic cornea can also be chosen by transplant patients who can't accept a human donor cornea.
The cornea in the eye serves several crucial functions, including safeguarding interior eye tissues, assisting with refractive power, and focusing light on the retina with minimal possible scatter and optical degradation. Depending on their severity, certain disorders require corneal transplantation, including Fuchs dystrophy, keratoconus, keratitis, corneal ulcers, corneal scarring, and corneal edema.
The market for corneal implants is expanding as corneal problems are becoming more common. Also, the rise in corneal blindness in developing nations and the demand for corneal transplants contribute to the market's expansion. The expansion of the corneal implant market is anticipated to be fueled by an increase in healthcare spending and infrastructure, a shift in government policy in the healthcare sector, an increase in disposable income, and the development of the pharmaceutical industry.
COVID-19 Impact Analysis
The COVID-19 pandemic had a damaging effect on the Corneal Implant market. To save cost and lower the danger of infection, many hospitals and clinics had to postpone or cancel non-urgent procedures, such as corneal transplants, which caused a significant setback for the corneal implants market. Particularly during the early stages of the pandemic, patients' hospital trips for non-essential treatments were restricted by the severe lockdown regulations imposed by the local and national authorities. The classification of ophthalmic procedures, such as keratoplasty and sight-restoring surgeries, as elective surgical procedures that can be postponed further hindered the market's financial performance.
Market Growth Factors
Rising cases of corneal blindness and other vision impairment diseases
With an estimated 10 million patients diagnosed with bilateral corneal blindness globally, corneal disorders are one of the leading causes of blindness. At 3.2% of all cases, corneal opacity ranks amongst the world's most common causes of blindness. Six million people, including 2 million with trachoma, have cornea-related blindness or moderate to severe visual impairment, according to a new World Health Organization (WHO) report. Near- or distance vision impairment impacts approximately 2.2 billion people globally. At least 1 billion of these cases, roughly half involved vision impairment that could have been prevented or was not addressed.
The surging requirement for artificial cornea
The artificial cornea can overcome ocular surface disease, immunological rejection, and immune graft danger. The artificial cornea has reduced swellability, which means it will have less light scattering and water accumulation. A significant rate of growth is anticipated for corneal implant manufacturers due to the high prevalence of corneal blindness and the absence of corneal donors. Furthermore, the artificial cornea implant is anticipated to grow significantly due to the increasing prevalence of corneal infections. Thus, the presence of the artificial cornea with various benefits over the traditional one is expected to surge the corneal implant market growth. This will expedite the market's growth.
Market Restraining Factors
Issues restricting wider adoption of corneal implants
Most healthcare facilities in developing nations treat corneal implants as outpatient procedures. This has made corneal implants less popular in these parts of the world. If there isn't enough healthcare infrastructure in these areas, it would be hard for existing and new businesses to break into the market. Since promising alternatives have become available, the acceptance rate of intrastromal corneal ring segment implantation has been going down over the past few years. Thus, the need for high capital to establish surgery centers for cornea implants, lack of donors, and other factors are expected to hinder the market growth.
Procedure Type Outlook
Based on procedure type, the corneal implants market is segmented into penetrating keratoplasty, endothelial keratoplasty and others. The endothelial keratoplasty segment acquired a substantial revenue share in the corneal implants market in 2022. This is because the most recent kind of corneal transplant uses endothelial keratoplasty, which replaces only the damaged tissue rather than the entire thickness of the cornea. This procedure aids in quicker and better sight recovery due to its features like less possibilities of infection and eye surface injuries.
Disease Type Outlook
On the basis of disease type, the corneal implants market is divided into keratoconus, fuchs' dystrophy, infectious keratitis and others. The fuchs' dystrophy segment witnessed the largest revenue share in the corneal implants market in 2022. This is owing to the increased knowledge of ocular health and Fuchs' dystrophy being more common. The clear layer (cornea) on the front of the eye becomes clogged with fluid when a person has Fuchs' dystrophy, which causes the cornea to enlarge and thicken. As a result, glare, clouded or impaired vision, and eye discomfort may result.
End User Outlook
By end-user, the corneal implants market is classified into hospitals, ophthalmic centers and others. The hospitals segment registered the highest revenue share in the corneal implants market in 2022. This is due to the availability of highly qualified healthcare professionals and the expansion of private & group insurance plans' coverage of hospital-based healthcare services. Hospitals also have specialist equipment and facilities, such as operating rooms, intensive care units, and units for specialty eye surgery. Hence, with the presence of specialists and high-tech machinery to perform these surgeries, the hospital segment growth is expected to boost in the projected period.
Regional Outlook
Region-wise, the corneal implants market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the corneal implants market by generating the maximum revenue share in 2022. This is because of a rise in the infrastructure for healthcare and an increase in the prevalence of corneal illnesses. Also, a surge in the number of significant producers of artificial corneal implants and a rise in public awareness of health and well-being contribute to the market growth in this area. Furthermore, the prevalence of keratoconus is also anticipated to enhance demand for corneal implants, which is anticipated to spur market expansion in North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Presbia PLC, CorNeat Vision Ltd., Alcon, Inc., AJL Opthalmic SA, LinkoCare Life Sciences AB, CorneaGen, DIOPTEX GmbH, Mediphacos Industrias Medicas S.A., EyeYon Medical Ltd., and KeraMed, Inc.
Strategies Deployed in Corneal implants Market
Nov-2022: Alcon took over Aerie Pharmaceuticals, a US-based clinical-stage pharmaceutical company. The addition of Aerie expands Alcon's market presence in the ophthalmic pharmaceutical market. Moreover, Aerie's deep technical expertise supports the company's endeavor to develop a comprehensive portfolio of ophthalmic pharmaceuticals.
Apr-2022: CorneaGen introduced EndoSerter-PL, an FDA-approved insertion device. The single-use graft insertion device is equipped with masterly processed tissue to smoothen the DSEK surgeries.
Jan-2022: Alcon took over Ivantis, a US-based manufacturer of surgical devices for the treatment of eye diseases. The acquisition brings in Ivantis' Hydrus Microstent, which would be added to the acquiring company's global portfolio. Further, the addition of Ivantis reinforces Alcon's global surgical portfolio.
Jan-2022: CorneaGen signed an agreement with MellingMedical, a provider of pharmaceuticals, surgical, wound care, and etc. products. The agreement involves Melling providing Federal Health facilities with CorneaGen tissue. The partnership broadens CorneaGen's devotion to transforming the lives of people with corneal diseases, particularly America's veterans.
Jun-2021: EyeYon Medical for its EndoArt received CE Mark. EndoArt is a synthetic implant, which takes place of human endothelium that a body cannot regenerate. This approval enables the company to work in close relations with the healthcare providers to make patients live a better quality of life.
Mar-2021: CorNeat Vision came into partnership with LiveU and Alcon, a US-based provider of live video streaming services. Alcon is a US-based Ophthalmology company. The partnership focuses on implementing a remote surgeon virtual presence (RSVP) solution. The partnership involves cashing on Alcon's NGENUITY 3D Visualization System to carry out remote training of cornea experts located in Toronto. The partnership further boosts CorNeat's CorNeat KPro sales, as it would allow the company to train physicians across the world without physical presence.
Mar-2019: Alcon completed the acquisition of PowerVision, a US-based developer of implantable intraocular lenses. The acquisition reflects Alcon's devotion to driving forward the growth and innovation in AT-IOLS, advanced technology intraocular lenses.
Feb-2019: CorneaGen took over KeraLink Domestic Eye Bank Operations, a US-based provider of eye bank services. The acquisition broadens the company's surgical product offerings. Further, the addition of KeraLink Domestic Eye Bank Operations also brings in partnerships with industry and research communities which would further enhance the acquiring company's access to major and important discoveries in corneal disease treatment.
Market Segments covered in the Report:
By Disease Type
By Procedure Type
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research